Which has higher earnings and valuation, LMAT or ITGR?

Integer has higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $262.43M 7.02 $57.73M $2.85 28.28 Integer $1.85B 2.31 $102.81M $3.66 34.44

LeMaitre Vascular (LMAT) Competitors

$80.59 +1.79 (+2.27%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$80.58 -0.02 (-0.02%)

As of 09/11/2026 07:30 PM Eastern

Compare

LMAT vs. MMED, TFX, HAE, LIVN, and ITGR

Should you buy LeMaitre Vascular stock or one of its competitors? LeMaitre Vascular's main competitors and comparable companies include MiniMed Group (MMED), Teleflex (TFX), Haemonetics (HAE), LivaNova (LIVN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LeMaitre Vascular compare to MiniMed Group?

LeMaitre Vascular (NASDAQ:LMAT) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, MiniMed Group had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 3 mentions for MiniMed Group and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.81 beat MiniMed Group's score of 1.04 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Overall Sentiment
LeMaitre Vascular	Very Positive
MiniMed Group	Positive

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 0.0% of MiniMed Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

LeMaitre Vascular currently has a consensus target price of $110.60, indicating a potential upside of 37.24%. MiniMed Group has a consensus target price of $23.77, indicating a potential upside of 5.64%. Given LeMaitre Vascular's higher probable upside, research analysts clearly believe LeMaitre Vascular is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

LeMaitre Vascular has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$262.43M	7.02	$57.73M	$2.85	28.28
MiniMed Group	$3.22B	1.96	-$333M	-$0.68	N/A

LeMaitre Vascular has a net margin of 25.02% compared to MiniMed Group's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.63% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
MiniMed Group	N/A	N/A	N/A

Summary

LeMaitre Vascular beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

How does LeMaitre Vascular compare to Teleflex?

Teleflex (NYSE:TFX) and LeMaitre Vascular (NASDAQ:LMAT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

LeMaitre Vascular has a net margin of 25.02% compared to Teleflex's net margin of -39.67%. LeMaitre Vascular's return on equity of 15.63% beat Teleflex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
LeMaitre Vascular	25.02%	15.63%	10.06%

LeMaitre Vascular has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$2.25B	2.46	-$905.64M	-$23.29	N/A
LeMaitre Vascular	$262.43M	7.02	$57.73M	$2.85	28.28

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 0.7% of Teleflex shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Teleflex has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 1.0%. LeMaitre Vascular pays an annual dividend of $1.00 per share and has a dividend yield of 1.2%. Teleflex pays out -5.8% of its earnings in the form of a dividend. LeMaitre Vascular pays out 35.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. LeMaitre Vascular has increased its dividend for 14 consecutive years. LeMaitre Vascular is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Teleflex currently has a consensus target price of $152.90, suggesting a potential upside of 16.85%. LeMaitre Vascular has a consensus target price of $110.60, suggesting a potential upside of 37.24%. Given LeMaitre Vascular's higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Teleflex had 5 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Teleflex and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.81 beat Teleflex's score of 0.34 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Overall Sentiment
Teleflex	Neutral
LeMaitre Vascular	Very Positive

Summary

LeMaitre Vascular beats Teleflex on 12 of the 20 factors compared between the two stocks.

How does LeMaitre Vascular compare to Haemonetics?

Haemonetics (NYSE:HAE) and LeMaitre Vascular (NASDAQ:LMAT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

LeMaitre Vascular has a net margin of 25.02% compared to Haemonetics' net margin of 7.12%. Haemonetics' return on equity of 27.55% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
LeMaitre Vascular	25.02%	15.63%	10.06%

Haemonetics has higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.35B	3.45	$97.31M	$2.04	50.32
LeMaitre Vascular	$262.43M	7.02	$57.73M	$2.85	28.28

Haemonetics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Haemonetics currently has a consensus price target of $99.78, suggesting a potential downside of 2.80%. LeMaitre Vascular has a consensus price target of $110.60, suggesting a potential upside of 37.24%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Haemonetics had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 4 mentions for Haemonetics and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.81 beat Haemonetics' score of 0.94 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Overall Sentiment
Haemonetics	Positive
LeMaitre Vascular	Very Positive

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Haemonetics beats LeMaitre Vascular on 10 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to LivaNova?

LivaNova (NASDAQ:LIVN) and LeMaitre Vascular (NASDAQ:LMAT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, LivaNova had 6 more articles in the media than LeMaitre Vascular. MarketBeat recorded 7 mentions for LivaNova and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.81 beat LivaNova's score of 0.88 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Overall Sentiment
LivaNova	Positive
LeMaitre Vascular	Very Positive

LivaNova currently has a consensus price target of $84.13, indicating a potential upside of 7.60%. LeMaitre Vascular has a consensus price target of $110.60, indicating a potential upside of 37.24%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LivaNova has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LeMaitre Vascular has a net margin of 25.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
LeMaitre Vascular	25.02%	15.63%	10.06%

LeMaitre Vascular has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.10	-$242.47M	$3.38	23.13
LeMaitre Vascular	$262.43M	7.02	$57.73M	$2.85	28.28

Summary

LivaNova and LeMaitre Vascular tied by winning 8 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Integer?

LeMaitre Vascular (NASDAQ:LMAT) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

LeMaitre Vascular has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Integer has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

LeMaitre Vascular has a net margin of 25.02% compared to Integer's net margin of 6.97%. LeMaitre Vascular's return on equity of 15.63% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
Integer	6.97%	12.79%	6.48%

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Integer has higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$262.43M	7.02	$57.73M	$2.85	28.28
Integer	$1.85B	2.31	$102.81M	$3.66	34.44

LeMaitre Vascular currently has a consensus target price of $110.60, indicating a potential upside of 37.24%. Integer has a consensus target price of $109.86, indicating a potential downside of 12.86%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, analysts plainly believe LeMaitre Vascular is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

In the previous week, Integer had 6 more articles in the media than LeMaitre Vascular. MarketBeat recorded 7 mentions for Integer and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.81 beat Integer's score of 0.20 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Overall Sentiment
LeMaitre Vascular	Very Positive
Integer	Neutral

Summary

LeMaitre Vascular beats Integer on 9 of the 16 factors compared between the two stocks.

Get LeMaitre Vascular News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMAT vs. The Competition

Export

Metric	LeMaitre Vascular	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$5.38B	$7.13B	$12.72B
Dividend Yield	1.26%	1.79%	2.56%	11.15%
P/E Ratio	28.28	25.09	275.24	25.29
Price / Sales	7.02	82.90	656.02	98.94
Price / Cash	27.15	32.53	77.04	51.44
Price / Book	4.64	5.97	10.33	6.20
Net Income	$57.73M	$150.75M	$3.50B	$358.50M
7 Day Performance	-0.10%	-2.83%	-3.32%	-2.35%
1 Month Performance	-1.88%	-3.09%	-0.41%	-2.77%
1 Year Performance	-12.68%	9.34%	19.21%	7.63%

LeMaitre Vascular Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMAT LeMaitre Vascular	4.9047 of 5 stars	$80.59 +2.3%	$110.60 +37.2%	-14.5%	$1.84B	$262.43M	28.28	655	Positive News
MMED MiniMed Group	1.4526 of 5 stars	$22.54 +11.3%	$21.62 -4.1%	N/A	$6.33B	$3.10B	N/A	2,800	Positive News Analyst Upgrade
TFX Teleflex	4.2447 of 5 stars	$141.46 -0.4%	$152.90 +8.1%	-1.4%	$5.99B	$1.99B	N/A	15,500	Positive News
HAE Haemonetics	1.8246 of 5 stars	$102.93 -0.1%	$97.56 -5.2%	+91.7%	$4.68B	$1.33B	50.43	3,009
LIVN LivaNova	2.666 of 5 stars	$80.09 +0.4%	$83.50 +4.3%	+36.3%	$4.40B	$1.39B	23.61	3,300	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMAT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Competitors

LMAT vs. MMED, TFX, HAE, LIVN, and ITGR

How does LeMaitre Vascular compare to MiniMed Group?

Summary

How does LeMaitre Vascular compare to Teleflex?

Summary

How does LeMaitre Vascular compare to Haemonetics?

Summary

How does LeMaitre Vascular compare to LivaNova?

Summary

How does LeMaitre Vascular compare to Integer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LeMaitre Vascular (LMAT) Competitors

LMAT vs. MMED, TFX, HAE, LIVN, and ITGR

How does LeMaitre Vascular compare to MiniMed Group?

Does the media prefer LMAT or MMED?

Do insiders & institutionals hold more shares of LMAT or MMED?

Do analysts rate LMAT or MMED?

Which has higher earnings & valuation, LMAT or MMED?

Is LMAT or MMED more profitable?

Summary

How does LeMaitre Vascular compare to Teleflex?

Is TFX or LMAT more profitable?

Which has stronger valuation and earnings, TFX or LMAT?

Do institutionals & insiders have more ownership in TFX or LMAT?

Which has more risk and volatility, TFX or LMAT?

Is TFX or LMAT a better dividend stock?

Do analysts recommend TFX or LMAT?

Does the media favor TFX or LMAT?

Summary

How does LeMaitre Vascular compare to Haemonetics?

Is HAE or LMAT more profitable?

Which has preferable valuation & earnings, HAE or LMAT?

Which has more volatility and risk, HAE or LMAT?

Do analysts prefer HAE or LMAT?

Does the media prefer HAE or LMAT?

Do institutionals and insiders hold more shares of HAE or LMAT?

Summary

How does LeMaitre Vascular compare to LivaNova?

Does the media prefer LIVN or LMAT?

Do analysts recommend LIVN or LMAT?

Which has more risk & volatility, LIVN or LMAT?

Do institutionals & insiders believe in LIVN or LMAT?

Is LIVN or LMAT more profitable?

Which has stronger earnings and valuation, LIVN or LMAT?

Summary

How does LeMaitre Vascular compare to Integer?

Which has more volatility and risk, LMAT or ITGR?

Is LMAT or ITGR more profitable?

Do institutionals and insiders believe in LMAT or ITGR?

Which has higher earnings and valuation, LMAT or ITGR?

Do analysts rate LMAT or ITGR?

Does the media favor LMAT or ITGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools